Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy
- PMID: 16391708
- DOI: 10.1139/y05-068
Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy
Abstract
Activation of the renin-angiotensin-aldosterone system is associated with increased extracellular matrix and inflammatory markers in the cardiovascular system. We evaluated the effects of aldosterone antagonism on cardiovascular structure, collagen deposition, and expression of inflammatory markers in 2-week angiotensin (Ang) II-infused rats (120 ng.kg-1.min-1, s.c.)+/-spironolactone or hydralazine (25 mg.kg-1.d-1). Aortic and cardiac collagen density was evaluated with Sirius red staining. NFkappaB and AP-1 were measured by a electrophoretic mobility shift assay, and ED-1 (macrophage marker) and vascular cell adhesion molecule-1 (VCAM-1) were measured by immunohistochemistry. Ang II increased blood pressure (176+/-2 mmHg vs. 115+/-1 mmHg in controls, p<0.01), which was attenuated by spironolactone (147+/-4 mmHg, p<0.01) and prevented by hydralazine (124+/-2 mmHg, p<0.01). Ang II enhanced left ventricular interstitial collagen type I/III deposition (4.1%+/-0.1% vs. 3.1%+/-0.2%, p<0.05), and this was attenuated by spironolactone but not hydralazine. Ang II-induced cardiac perivascular fibrosis was prevented by spironolactone and hydralazine. Ang II significantly increased cardiac AP-1 activity and ED-1 expression, which was prevented by spironolactone only. Ang II-enhanced NFkappaB activity, and VCAM-1 expression was reduced by spironolactone and hydralazine, whereas aortic hypertrophy was prevented by spironolactone and slightly reduced by hydralazine. In conclusion, blockade of mineralocorticoid receptors with spironolactone inhibited Ang II-induced aortic hypertrophy, cardiac transcription factor activation, upregulation of downstream inflammatory markers, and collagen deposition, thus preventing Ang II-induced cardiovascular damage.
Similar articles
-
PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.J Mol Cell Cardiol. 2004 Feb;36(2):295-304. doi: 10.1016/j.yjmcc.2003.11.004. J Mol Cell Cardiol. 2004. PMID: 14871557
-
Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):365-71. doi: 10.1161/01.ATV.0000152356.85791.52. Epub 2004 Dec 2. Arterioscler Thromb Vasc Biol. 2005. PMID: 15576638
-
Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension.Clin Sci (Lond). 2002 Aug;103 Suppl 48:25S-30S. doi: 10.1042/CS103S025S. Clin Sci (Lond). 2002. PMID: 12193048
-
[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].Praxis (Bern 1994). 1997 Apr 2;86(14):566-74. Praxis (Bern 1994). 1997. PMID: 9198851 Review. German.
-
[Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].Praxis (Bern 1994). 1996 Feb 20;85(8):227-33. Praxis (Bern 1994). 1996. PMID: 8701189 Review. German.
Cited by
-
Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta.Endocrinology. 2009 May;150(5):2229-36. doi: 10.1210/en.2008-1296. Epub 2008 Dec 23. Endocrinology. 2009. PMID: 19106220 Free PMC article.
-
Blood pressure response to angiotensin II is enhanced in obese Zucker rats and is attributed to an aldosterone-dependent mechanism.Br J Pharmacol. 2012 Aug;166(8):2417-29. doi: 10.1111/j.1476-5381.2012.01953.x. Br J Pharmacol. 2012. PMID: 22452651 Free PMC article.
-
Glucocorticoids activate cardiac mineralocorticoid receptors in adrenalectomized Dahl salt-sensitive rats.Nagoya J Med Sci. 2014 Feb;76(1-2):59-72. Nagoya J Med Sci. 2014. PMID: 25129992 Free PMC article.
-
Aldosterone and the heart: still an unresolved issue?Front Endocrinol (Lausanne). 2014 Oct 14;5:168. doi: 10.3389/fendo.2014.00168. eCollection 2014. Front Endocrinol (Lausanne). 2014. PMID: 25352832 Free PMC article. Review.
-
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.Kidney Int. 2009 May;75(9):936-44. doi: 10.1038/ki.2009.9. Epub 2009 Feb 18. Kidney Int. 2009. PMID: 19225557 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous